# A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor

> **NCT07140393** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** HRS-4508+ Capecitabine
- **DRUG:** HRS-4508+ Trastuzumab
- **DRUG:** HRS-4508+ Trastuzumab+ Pertuzumab
- **DRUG:** HRS-4508+ Trastuzumab+ Capecitabine
- **DRUG:** Trastuzumab+ Capecitabine
- **DRUG:** HRS-4508+A1811

## Key facts

- **NCT ID:** NCT07140393
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10
- **Primary completion:** 2027-10
- **Final completion:** 2028-10
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07140393

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07140393, "A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT07140393. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*